- GlycoMimetics (GLYC +10%) reports that development partner Pfizer (PFE +0.5%) and the FDA have agreed on the special protocol assessment (SPA) for the planned Phase 3 clinical trial for rivipansel as a treatment for patients with sickle cell disease who are hospitalized for vaso-occlusive crisis. Pfizer intends to start the trial before the end of 2014.
- Rivipansel is both Orphan Drug and Fast Track-designated.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs